StockNews.AI
CHRS
StockNews.AI
169 days

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

1. Coherus will release Q4 and full year 2024 results on March 10, 2025. 2. Management will host a conference call to discuss financials and business updates. 3. Coherus focuses on immunotherapies and markets LOQTORZI®, a PD-1 inhibitor. 4. Pipeline includes promising candidates like Casdozokitug and CHS-114. 5. Company is complying with Regulation FD for disclosure of information.

Earnings
-5.03%Current Return
VS
-3.37%S&P 500
$1.100303/03 09:35 AM EDTEvent Start
$1.04503/04 03:56 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings report could reveal positive financial growth and pipeline updates. Similar companies often see stock price increases after favorable earnings announcements.

How important is it?

High relevance due to forthcoming financial results which can impact stock valuation directly.

Why Short Term?

The financial results release is imminent, likely influencing immediate trading behavior.

Related Companies

JNJAMGNBMY
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, March 10, 2025, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BIddb737c625d842e0867fa22a43106197 Webcast: https://edge.media-server.com/mmc/p/3dwbidfe The press release with the fourth quarter and full year 2024 financial results and related materials will be available at https://investors.coherus.com/ before the start of the conference call. A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations following the conclusion of the live conference call. Please dial in 15 minutes early to ensure a timely connection to the call. Disclosure Information Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.  About CoherusCoherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and is developing an innovative immuno-oncology pipeline that is expected to synergize with its proven commercial capabilities in oncology. Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in three ongoing clinical studies: a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, cytolytic anti-CCR8 antibody currently in a Phase 1 study in patients with advanced solid tumors, including HNSCC. Coherus Contact InformationInvestors:Jodi SieversVP, Investor Relations & Corporate CommunicationsIR@coherus.com

Related News